Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197
about
MET inhibitors in combination with other therapies in non-small cell lung cancerDiscoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discoveryA Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases: DISCOVERY OF ATP-INDEPENDENT INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTORMolecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinomaProfile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to datePhase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancerMET as a possible target for non-small-cell lung cancer.Targeting the HGF/Met signaling pathway in cancer therapyCytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.The progress of targeted therapy in advanced gastric cancerTargeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsMET: a promising anticancer therapeutic target.Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.Tivantinib in hepatocellular carcinoma.Natural product and natural product derived drugs in clinical trials.Tivantinib: critical review with a focus on hepatocellular carcinoma.Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinibMET: a new promising biomarker in non-small-cell lung carcinoma.Promise and challenges on the horizon of MET-targeted cancer therapeuticsNovel drugs in clinical development for hepatocellular carcinoma.Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.
P2860
Q26823203-693C74D9-9E11-4E2C-9434-F090830DC636Q26853215-89670152-9C43-4B14-9AFF-BDCE4CF275BAQ27667388-BDC41665-EF88-4FDD-97A1-2B374FBA812DQ27683971-21BD9E25-93DE-4727-863D-E1CAB3ED2C0FQ28070762-4303D323-6EA2-45AB-8A5A-7F482DBC4E97Q28071589-E1567CD2-0625-4420-A8A3-83D2B70FB8DEQ33168449-35EB2A1D-CC9F-4FF1-97F5-23319B93EB86Q33769429-584C2F24-1C18-4C9A-8DCF-6271AD768B73Q33830522-7926E4B9-544D-49B8-8BD8-B847724981F8Q34182679-F48C024A-641A-4EC7-B825-1B0B8BA3A4F0Q35146597-CB2EB63A-C971-418A-9B96-01DBEFD0B058Q35214544-F7A9F575-561B-4F50-A512-5B344E4384E3Q35824064-3E336735-A936-4CF4-9F4F-CBD1ADFA5681Q35896530-8F719928-A1C3-4FFB-8952-9836148B1A41Q36574080-17448941-61E9-42DF-823B-479B07BDC1CCQ36660673-D18E6734-FBEC-4DB2-A341-9EFEC08B5ACCQ37013777-42C3EC28-1F09-4D3D-A81B-843ECA142D3AQ37137050-EEBF8D8C-05A6-49CA-8AA4-D13630309727Q37293444-541A21FD-6846-4936-8021-13D858C28522Q37352553-E45BCD8B-7CDD-44B5-B862-647BFC7A8382Q37427269-94CC7167-91C8-40DE-8F3B-42ABBE952736Q37427337-267DD6DA-0579-4B7A-96FA-842BD2957193Q37620336-E2408C10-880C-4EF4-8FA1-66B9D78660BCQ38008247-F308321A-52D6-480D-872A-3D291AE6CEB2Q38056554-A69E30E1-9ABA-4608-AF99-64C63F11C6E4Q38061201-9D2B9823-3237-4537-B392-051A4796F180Q38247457-419FF0D1-57A0-4907-B1FA-28D1591C6C1FQ38259343-1991ABE2-FA2C-4258-99ED-690EC2F76B66Q38261315-55A5201C-D260-4AB5-AD1A-9BF176168D01Q38430194-AA5D51D6-0C1B-48A0-9DD5-83751E06E290Q38502350-DEBC06C3-BC82-4E0B-8C89-3714292A398AQ38537138-034C5B03-E6DC-4F98-B0EC-2D89359B34D9Q38625550-B5626B48-2F82-4A65-B366-27599D5E80BBQ38704262-DB073A7A-5D76-4B69-BDDD-00518E46B3A9Q38723404-18D236DF-B8FC-4AB6-A8E8-82AF9A27E800Q38771978-CB9D0267-CF14-4E1D-AC2E-2B4DD886BB53Q38844872-CBC1771A-2398-40DE-A057-83ABB47A09BCQ38856729-BADBC4D3-BADC-425B-8BE0-6E313FFA035CQ38956071-DBEEC448-4B32-4FBD-8102-AED644E534A2Q38986669-9A82278F-737A-4A99-A1D8-751D0152C506
P2860
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@ast
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@en
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@nl
type
label
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@ast
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@en
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@nl
altLabel
Discovery of a Novel Mode of P ...... Autophosphorylation by ARQ 197
@en
prefLabel
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@ast
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@en
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@nl
P2093
P2860
P3181
P356
P1476
Discovery of a novel mode of p ...... autophosphorylation by ARQ 197
@en
P2093
Dennis S France
Erika Volckova
Mark A Ashwell
Marscha Hirschi
Rocio Palma
Sudharshan Eathiraj
Thomas C K Chan
P2860
P304
P3181
P356
10.1074/JBC.M110.213801
P407
P577
2011-06-10T00:00:00Z